Phuturdex › Diseases › Obesity
Drugs in development · updated 30 October 2026
Obesity: drugs in development
As of 30 October 2026 there are 415 active clinical trials (recruiting or ongoing, phases I–III) on 233 drugs for obesity. 165 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
Sorted by most advanced phase and number of active trials. Showing 40 of 165 drugs.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| SemaglutideWegovy, Rybelsus | II–III | 60 | NCT07891156 |
| TirzepatideZepbound, Mounjaro | II–III | 55 | NCT07846865 |
| OrforglipronFoundayo® | III | 10 | NCT07790861 |
| MetforminRiomet Er®, Glumetza® | III | 7 | NCT07297290 |
| BupropionForfivo Xl®, Aplenzin® | III | 3 | NCT07806279 |
| Letrozoleoral Femara | II–III | 2 | NCT06379113 |
| LiraglutideSaxenda®, Victoza® | III | 2 | NCT04775082 |
| MirikizumabOmvoh® | III | 2 | NCT06937099 |
| AspirinVazalore®, Durlaza® | III | 1 | NCT06952712 |
| Cholecalciferol | III | 1 | NCT03516968 |
| DasatinibPhyrago®, Sprycel® | II–III | 1 | NCT05653258 |
| LevothyroxineLevothyroxin, Synthroid | III | 1 | NCT07332273 |
| Megestrol AcetateMegace Es®, Megace® | II–III | 1 | NCT05316493 |
| Sacubitril∙ValsartanEntresto Pill, Neparvis® | II–III | 1 | NCT04971720 |
| SufentanilDsuvia®, Sufenta Preservative Free® | III | 1 | NCT07844512 |
Sorted by most advanced phase and number of active trials. Showing 15 of 68 drugs.
All 233 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Pediatric Obesity 11 drugs
- Prader–Willi syndrome 5 drugs
- Prediabetes 18 drugs
- Morbid obesity 3 drugs
- Weight loss 26 drugs
- Insulin resistance 41 drugs
- Type 2 diabetes 171 drugs
- Glucose intolerance 6 drugs
- Non-alcoholic Fatty Liver Disease 68 drugs
- Obstetric labor complication 4 drugs
- Overweight 139 drugs
- Frailty syndrome 15 drugs
Broader categories
- Nutritional and metabolic diseases 5 drugs
- Overnutrition 5 drugs
- Nutrition disorder 10 drugs
- Human body weight 13 drugs
- Overweight 139 drugs
- Metabolic disease 30 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D009765 “Obesity”.